TABLE 2.
Real‐World Overall Survival for Common Treatment Sequences
| Sequence | Patients, no. (%) a | Median (95% CI) rwOS, b months |
|---|---|---|
| One‐line sequences | ||
| Gem/nab | 1752 (30.8) | 5.1 (4.7‐5.4) |
| FOLFIRINOX | 712 (12.5) | 5.8 (5.4‐6.4) |
| Gem monotherapy | 389 (6.8) | 3.5 (3.2‐4.0) |
| FOLFOX | 134 (2.4) | 3.4 (3.0‐4.6) |
| Two‐line sequences | ||
| FOLFIRINOX >> gem/nab | 346 (6.1) | 11.0 (10.5‐12.0) |
| Gem/nab >> FOLFIRINOX | 132 (2.3) | 10.3 (9.0‐11.3) |
| Gem/nab >> liposomal irinotecan +5‐FU/LV | 122 (2.1) | 11.5 (10.5‐12.7) |
| Gem/nab >> FOLFOX | 114 (2.0) | 10.3 (9.1‐11.6) |
| Gem/nab >> capecitabine | 54 (0.9) | 9.9 (8.5‐12.5) |
| Three‐line sequences | ||
| FOLFIRINOX >> gem/nab >> liposomal irinotecan +5‐FU/LV | 36 (0.6) | 17.7 (12.1‐19.5) |
| Gem/nab >> FOLFIRINOX >> liposomal irinotecan +5‐FU/LV | 14 (0.2) | 13.7 (7.6‐21.8) |
Abbreviations: >>, therapy advanced from one line to another; 5‐FU, 5‐fluorouracil; CI, confidence interval; FOLFIRINOX, 5‐fluorouracil + leucovorin + non‐liposomal irinotecan + oxaliplatin; FOLFOX, 5‐fluorouracil + leucovorin + oxaliplatin; gem/nab, gemcitabine + nanoparticle albumin‐bound paclitaxel; LV, leucovorin; rwOS, real‐world overall survival.
a
Reflects the number of patients who advanced through one, two, or three lines of therapy, receiving a particular one‐, two‐, or three‐line sequence; expressed as a percentage of all patients who received at least one line of therapy (n = 5687).
b
rwOS is measured from the start of each line of therapy